چاپ صفحه |  صفحه نخست سامانه |  چکیده مقاله |  نویسندگان |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| Background: Multiple sclerosis (MS) is an inflammatory autoimmune disease characterized by neurodegeneration in the CNS. Interferon-beta (IFN-β) is an FDA-approved drug used as the first-line treatment for relapseremitting multiple sclerosis (RRMS). The exact mechanism of IFN-β during the treatment of RRMS still remains unknown. Recently, many studies have shifted towards the role of miRNAs in the treatment of MS patients. Methods: Herein, the expression level of miR-185–5p and miR-320a has been evaluated in order to candidate them as novel biomarkers for monitoring the response to IFN-β therapy. For this purpose, one-hundred whole blood samples from patients with RRMS were collected, consisting of 50 responders and 50 non-responders to IFN-β therapy. To predict the possible molecular mechanisms of IFN-β and highlight the role of these miRNAs, in silico analysis was applied to enrich the signaling pathways which may be involved based on the target genes of miR-185–5p and miR-320a. Results: It is identified that the differentially expressed miR-185–5p was statistically significant between the two treated groups with IFN-β. Furthermore, MAPK signaling pathway was suggested as the main non-canonical pathway involved in IFN-β therapy. Conclusion: miR-185–5p could be considered as a novel biomarker for monitoring the response to IFN-β therapy. |
| نویسنده | نفر چندم مقاله |
|---|---|
| سید رضا موسوی | اول |
| مهسا طهماسبی وند | دوم |
| هرمز آیرملو | چهارم |
| رضا ریخته گر غیاثی | هفتم |
| بهاره خادمی | هشتم |
| زهرا بهمن پور | نهم |
| بابک امامعلی زاده | دهم |
| سودابه خلیل خلیلی | پنجم |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| 1-s2.0-S2211034820303400.pdf | 1399/04/15 | 2406048 | دانلود |
